ALR Technologies

ALR Technologies SG Ltd. announced a letter of intent to acquire 100% of CGM Medical Technology Singapore Pte. Ltd.’s equity and assets of CGM Medical Technology Shenzhen Ltd. for 200 million ordinary shares and US$45 million, subject to conditions.

(May 19th, 2026 -- Singapore) ALR Technologies SG Ltd. (“ALRT” or the “Company”) (OTC: ALRTF), the diabetes management company, announces the GluCurve Pet CGM (“GluCurve”) is now for sale in Canada at (www.GluCurve.ca).

ALR Technologies SG Ltd. completed internal manufacturing tests of GluCurve Pet CGM, reporting accuracy comparable to a veterinary BGM, and scheduled its Canadian relaunch for January 2026.

ALR Technologies announces, announces it has entered into a Letter of Intent (“LOI”) to acquire 100% equity of CGM Medical Technology Singapore Pte. Ltd.

ALRT is dedicated to creating more effective chronic care management, sustainably providing measurable health information and enabling frequent patient/provider interactions, thus enhancing adherence to care plans, improving outcomes and containing healthcare costs.

The company provides assistance with questions.

The company develops solutions for sustainably providing measurable health information and enabling frequent patient-provider interactions. Its technology supports adherence to care plans, improves outcomes, and contains healthcare costs.

ALR Technologies SG Ltd. offers the GluCurve iOS and Android apps and a web-based interface, along with related information, software, accounts, products, communications and services, subject to its terms.

ALR Technologies SG Ltd. offers the ALRT iOS and Android apps and a web-based interface, along with related information, software, accounts, products, communications and services, subject to its terms.